动脉自旋标记成像对贝伐珠单抗治疗下高级别胶质瘤复发后预后的预测价值
本研究纳入32例在贝伐珠单抗治疗期间复发的高级别胶质瘤患者,用动脉自旋标记成像测量复发灶相对脑血流量(rCBF),回顾性分析其与预后的相关性。结果显示预测预后的最佳rCBF截断值为1.67,rCBF<1.67组的总生存期和无进展后生存期均显著长于rCBF≥1.67组。作者认为复发灶的rCBF值可能作为贝伐珠单抗治疗患者预后的有效影像生物标志物。
要点
- 预测预后的最佳rCBF截断值为1.67(ROC曲线分析)。
- rCBF<1.67组总生存期34.0个月,长于rCBF≥1.67组的13.0个月(p=0.03)。
- rCBF<1.67组无进展后生存期13.0个月,长于rCBF≥1.67组的6.0个月(p<0.001)。
核心结论
- 复发灶的ASL衍生rCBF值可能作为接受贝伐珠单抗治疗的高级别胶质瘤患者预后的有效影像生物标志物。
- 低rCBF值可能提示贝伐珠单抗疗效可持续,这将影响高级别胶质瘤患者的贝伐珠单抗治疗策略。
研究设计与样本
- 回顾性研究,纳入32例(男20例、女12例;年龄范围35-84岁)在贝伐珠单抗治疗期间复发的高级别胶质瘤患者。
- 用动脉自旋标记成像测量每个复发灶的相对脑血流量(rCBF)值,回顾性分析rCBF值与预后的相关性。
主要发现
- 用受试者工作特征曲线分析确定预测预后的最佳rCBF截断值为1.67。
- rCBF<1.67组的总生存期为34.0个月,长于rCBF≥1.67组的13.0个月(p=0.03)。
- rCBF<1.67组的无进展后生存期为13.0个月,长于rCBF≥1.67组的6.0个月(p<0.001)。
关键数值与推荐
- 预测预后的最佳rCBF截断值为1.67(受试者工作特征曲线分析)。
- rCBF<1.67组 vs rCBF≥1.67组:总生存期34.0个月 vs 13.0个月(p=0.03)。
- rCBF<1.67组 vs rCBF≥1.67组:无进展后生存期13.0个月 vs 6.0个月(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Currently, the antiangiogenic agent bevacizumab (BVZ) is used as a treatment option for high-grade glioma (HGG) patients. However, BVZ restores disruptions of the blood-brain barrier, which leads to the disappearance of contrast enhancement during radiological examinations and therefore complicates evaluations of treatment efficacy. This study aimed to investigate the radio-morphological features of recurrent lesions that newly appeared under BVZ therapy, as well as the utility of arterial spin labeling (ASL) perfusion imaging for evaluating treatment response and prognosis in HGG patients receiving BVZ. METHODS: Thirty-two patients (20 males, 12 females; age range, 35-84 years) with HGG who experienced a recurrence under BVZ therapy were enrolled. We measured the relative cerebral blood flow (rCBF) values of each recurrent lesion using ASL, and retrospectively investigated the correlation between rCBF values and prognosis. RESULTS: The optimal rCBF cut-off value for predicting prognosis was defined as 1.67 using receiver operating characteristic curve analysis. The patients in the rCBF < 1.67 group had significantly longer overall survival (OS) and post-progression survival (PPS) than those in the rCBF ≥ 1.67 group (OS: 34.0 months vs. 13.0 months, p = 0.03 and PPS: 13.0 months vs. 6.0 months, p < 0.001, respectively). CONCLUSION: The ASL-derived rCBF values of recurrent lesions may serve as an effective imaging biomarker for prognosis in HGG patients undergoing BVZ therapy. Low rCBF values may indicate that BVZ efficacy is sustainable, which will influence BVZ treatment strategies in HGG patients.
引用
- Kambe A, Kitao S, Ochiai R, et al. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment. J Neurooncol. 2024. PMID: 38165552. doi:10.1007/s11060-023-04550-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。